Savara Inc. Class Action Lawsuit - SVRA

The filed complaint alleges that Savara Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI’s chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv) delay in MOLBREEVI’s regulatory approval increased the likelihood that the Company would need to raise additional capital; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

In order to be eligible to join the SVRA class action lawsuit, you must have incurred a loss on shares of Savara Inc. purchased during the class period listed above.

If you suffered a loss in Savara Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until November 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.